Oncolytic Zika virus therapy leverages CCR2+ monocytes to boost anti-glioblastoma T cell responses - PubMed
6 hours ago
- #Glioblastoma
- #Zika virus
- #Immunotherapy
- Glioblastoma (GBM) is a lethal brain tumor with limited treatment options due to immune suppression in the tumor microenvironment (TME).
- Oncolytic Zika virus (ZIKV) selectively targets glioma stem cells (GSCs) and remodels the TME to enhance anti-tumor CD8+ T cell responses.
- ZIKV induces clonal expansion of tumor-infiltrating CD8+ T cells, increasing granzyme B and perforin-1 while reducing exhaustion markers.
- CCR2+ monocytes are essential for recruiting, proliferating, and activating anti-tumor CD8+ T cells in the TME.
- Disrupting monocyte trafficking or function impairs cytotoxic T cell responses and recruitment.
- ZIKV-driven CCR2+ monocyte activation enhances CD8+ T cell cytotoxicity and reduces exhaustion, offering a new therapeutic strategy for GBM.